Litigation-related charges 334
Restructuring charges 20
Acquisition-related milestone (250)
Loss on assets held for sale 352
1,295 1,620
Operating income (loss) 28 (147)
Other income (expense):
Interest expense (112) (147)
Other, net 16 35
Loss before income taxes (68) (259)
Income tax (benefit) expense (6) 13
Net loss $(62) $(272)
Net loss per common share - basic $(0.04) $(0.18)
Net loss per common share - assuming
dilution $(0.04) $(0.18)
Weighted average shares outstanding -
basic 1,500.9 1,489.8
Weighted average shares outstanding -
assuming dilution 1,500.9 1,489.8
BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
(Unaudited)
Three Months Ended Three Months Ended
September 30, 2008 September 30, 2007
Impact per Impact per
In millions, except per Net (loss) diluted Net (loss) diluted
share data income share income share
GAAP results $(62) $(0.04) $(272) $(0.18)
Non-GAAP adjustments:
Acquisition-related (credits)
charges
'/>"/>
SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Related biology technology :1.
Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet2.
Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders3.
Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent4.
Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels5.
Boston Scientific to Participate in UBS Global Life Sciences Conference6.
Boston Scientific Announces Court Decision7.
IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts8.
InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th9.
NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program10.
TechCFO Adds Gary Strickland as Partner in Boston Office11.
Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System